There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Astria Therapeutics (ATXS – Research Report) and uniQure (QURE – Research Report) with bullish sentiments.
Discover the Best Stocks and Maximize Your Portfolio:
Astria Therapeutics (ATXS)
In a report released today, Sam Slutsky from LifeSci Capital maintained a Buy rating on Astria Therapeutics, with a price target of $22.00. The company’s shares closed last Thursday at $6.42, close to its 52-week low of $6.24.
According to TipRanks.com, Slutsky has 0 stars on 0-5 stars ranking scale with an average return of -5.2% and a 32.4% success rate. Slutsky covers the Healthcare sector, focusing on stocks such as Third Harmonic Bio, Inc., Abivax SA Sponsored ADR, and Olema Pharmaceuticals.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Astria Therapeutics with a $24.20 average price target, a 281.7% upside from current levels. In a report issued on February 18, JMP Securities also reiterated a Buy rating on the stock with a $26.00 price target.
See the top stocks recommended by analysts >>
uniQure (QURE)
In a report released today, Joseph Thome from TD Cowen maintained a Buy rating on uniQure. The company’s shares closed last Thursday at $11.99.
According to TipRanks.com, Thome is a 2-star analyst with an average return of 0.0% and a 41.7% success rate. Thome covers the Healthcare sector, focusing on stocks such as Intra-Cellular Therapies, Entrada Therapeutics Inc, and Viridian Therapeutics.
uniQure has an analyst consensus of Strong Buy, with a price target consensus of $33.45, implying a 198.4% upside from current levels. In a report released today, William Blair also maintained a Buy rating on the stock.
Read More on ATXS: